Ketohexokinase Isoforms in Endometrial Cancer.
- Conditions
- Endometrial Cancer
- Registration Number
- NCT03931265
- Lead Sponsor
- Far Eastern Memorial Hospital
- Brief Summary
Our preliminary analysis with clinical database suggested that, in patients with type I endometrial cancer, high ketohexokinase-expressing group have lower survival probabilities than low ketohexokinase-expressing group. To understand the importance of ketohexokinase expression and isoform switch during the development of type I endometrial cancer, we propose a series of in vitro experiments and clinical examinations in this project.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 220
- >20 years
- Women with endometrial cancer who are about to be admitted to hospital for gynecological staging.
- Women who have undergone gynecological staging surgery for endometrial cancer in the past.
- Women with endometrial cancer who receive preoperative chemotherapy or radiation therapy.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The role of ketohexokinase isoforms in the overall survival of endometrial cancer. 5 years Cox proportional hazard regression to evaluate the role of ketohexokinase isoforms in the overall survival of endometrial cancer.
- Secondary Outcome Measures
Name Time Method Correlation of ketohexokinase isoforms with the other prognostic risk factors 5 years Correlation of ketohexokinase isoforms with deep myometrial invasion, tumor grade, lymph node metastasis, FIGO stage, tumor size, progression-free survival, etc.
Trial Locations
- Locations (1)
Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital
🇨🇳Banqiao, New Taipei, Taiwan